Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

SanBio Co stock price, quote, forecast and news

4592.T
JP3336750009
A14SRH

Price

920.00
Today +/-
-0.24
Today %
-3.94 %
P

SanBio Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the SanBio Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the SanBio Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the SanBio Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze SanBio Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

SanBio Co Stock Price History

DateSanBio Co Price
9/11/2024920.00 undefined
9/10/2024957.00 undefined
9/9/2024952.00 undefined
9/6/2024938.00 undefined
9/5/2024971.00 undefined
9/4/2024980.00 undefined
9/3/2024996.00 undefined
9/2/2024996.00 undefined
8/30/20241,046.00 undefined
8/29/2024995.00 undefined
8/28/2024990.00 undefined
8/27/20241,011.00 undefined
8/26/20241,039.00 undefined
8/23/20241,011.00 undefined
8/22/2024997.00 undefined
8/21/20241,023.00 undefined
8/20/20241,096.00 undefined
8/19/20241,023.00 undefined
8/16/20241,001.00 undefined
8/15/20241,040.00 undefined

SanBio Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SanBio Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SanBio Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SanBio Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SanBio Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SanBio Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SanBio Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SanBio Co’s growth potential.

SanBio Co Revenue, EBIT and net profit per share

DateSanBio Co RevenueSanBio Co EBITSanBio Co Net Income
2027e2.89 B undefined0 undefined-2.6 B undefined
2026e1.13 B undefined0 undefined-3.25 B undefined
2025e2.83 B undefined0 undefined-3.72 B undefined
20240 undefined-4.54 B undefined-2.64 B undefined
20230 undefined-7.9 B undefined-5.56 B undefined
20220 undefined-6.62 B undefined-4.68 B undefined
20210 undefined-5.8 B undefined-3.39 B undefined
2020447.23 M undefined-5.49 B undefined-5.16 B undefined
2019741.61 M undefined-3.73 B undefined-2.92 B undefined
2018490.51 M undefined-4.38 B undefined-3.94 B undefined
2017949.54 M undefined-1.93 B undefined-1.84 B undefined
20161.17 B undefined-1.13 B undefined-988.4 M undefined
20153.23 B undefined2.25 B undefined1.74 B undefined
2014204.3 M undefined-584.2 M undefined-589.5 M undefined

SanBio Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201420152016201720182019202020212022202320242025e2026e2027e
0.23.231.170.950.490.740.4500002.831.132.89
-1,482.84-63.64-19.17-48.3751.22-39.68------60.15156.26
---98.21----------
0009320000000000
-0.582.25-1.13-1.93-4.38-3.73-5.49-5.8-6.62-7.9-4.54000
-286.2769.65-95.83-203.58-893.47-503.78-1,227.29-------
-0.591.74-0.99-1.84-3.94-2.92-5.16-3.39-4.68-5.56-2.64-3.72-3.25-2.6
--394.74-156.9185.73114.71-25.8976.61-34.3638.1718.86-52.4440.66-12.66-20.07
38.239.1843.644.8945.3748.5451.1151.7951.7957.9265.32000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The SanBio Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the SanBio Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (k)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20142015201620172018201920202021202220232024
                     
0.441.237.735.564.6512.4513.6512.484.566.734.45
10017.350000000
00000000000
000000469.6444.52467.8500
1529.47457.6545.79422.01605.88510.38207.24326.66234.49482.65
0.461.268.196.125.0813.0614.6313.135.356.974.94
1918.2867.97148.37100.9174.17123.94141.7858.7547.8644.32
00000828.83824.520000
00000000000
00.060.217.75.352.613.6553.6566.281.2943.89
00000000000
1478.7611.3411.7810.4711.4717.2516.4734.3628.721.71
20497.179.52167.85116.73917.06979.36211.9159.3977.85109.92
0.481.768.276.295.1913.9815.6113.345.517.055.05
                     
00.093.813.853.889.438.085.564.086.413.32
3.713.87.527.567.5913.1411.89.277.7910.127.03
-5,727-3,989.72-4,978.21-6,798.68-10,735.09-13,639.54-8,913.08-7,140.46-8,730.93-7,728.46-1,744.55
4811.8319.36-21.64126.94145.29140.16657.65-1,094.79-4,367.55-5,806.57
00000-171.15-175.450000
-1.96-0.096.374.60.858.9110.938.352.044.432.79
0000000001,0000
6569.9336.52215.34202.46157.9339.9561.93473.56375.47494.85
2.370.210.480.181.840.880.340.430.480.450.14
0100100100000500000
0080049.9866.6433.38500975512.5268268
2.440.381.420.552.111.071.182.471.461.090.91
01.10.31.152.2343.52.532.010.670.4
00184.93000000860.93952.25
00000000000
01.10.481.152.2343.52.532.011.531.35
2.441.481.91.74.345.074.684.993.482.622.25
0.481.398.276.295.1913.9815.6113.345.517.055.05
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of SanBio Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand SanBio Co's financial health and stability.

Assets

SanBio Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that SanBio Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of SanBio Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into SanBio Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
-0.592.23-1.17-2.17-3.94-2.92-5.16-3.21-4.56-4.7
4514265336397413224
0000000000
0.47-2.47-0.23-0.072.55-0.3-0.230.41-0.210.36
22122409-571-784-374-2,492-1,906-3,117
061810243247494525
00013001518789
-111-218-1,362-1,796-1,906-3,968-5,717-5,215-6,546-7,434
-10-3-60-97-32-6-106-138-56-8
0.52-0.48-0.440.080.66-1.01-0.114.18-0.07-0.01
0.53-0.48-0.380.180.69-1-0.014.32-0.01-0
0000000000
0000.111.73-0.030-1.48-1.59
00.177.40.090.0510.957.070010.96
01.377.40.160.9812.727.02-0.06-1.59.45
000-30-6340-11-56-2481
0000000000
0.40.795.66-2.01-0.227.81.19-1.17-7.922.12
-121.6-221.61-1,422.18-1,893.54-1,939.26-3,974.7-5,824.24-5,354.44-6,602.74-7,442.15
0000000000

SanBio Co stock margins

The SanBio Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SanBio Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SanBio Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SanBio Co's sales revenue. A higher gross margin percentage indicates that the SanBio Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SanBio Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SanBio Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SanBio Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SanBio Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SanBio Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SanBio Co Margin History

SanBio Co Gross marginSanBio Co Profit marginSanBio Co EBIT marginSanBio Co Profit margin
2027e98.19 %0 %-89.91 %
2026e98.19 %0 %-288.24 %
2025e98.19 %0 %-131.53 %
202498.19 %0 %0 %
202398.19 %0 %0 %
202298.19 %0 %0 %
202198.19 %0 %0 %
202098.19 %-1,226.69 %-1,153.27 %
201998.19 %-503.49 %-393.81 %
201898.19 %-892.62 %-803.31 %
201798.19 %-203.49 %-193.28 %
201698.19 %-95.79 %-84.14 %
201598.19 %69.67 %53.77 %
201498.19 %-285.95 %-288.55 %

SanBio Co Stock Sales Revenue, EBIT, Earnings per Share

The SanBio Co earnings per share therefore indicates how much revenue SanBio Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SanBio Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SanBio Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SanBio Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SanBio Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

SanBio Co Revenue, EBIT and net profit per share

DateSanBio Co Sales per ShareSanBio Co EBIT per shareSanBio Co Earnings per Share
2027e42.08 undefined0 undefined-37.83 undefined
2026e16.42 undefined0 undefined-47.33 undefined
2025e41.21 undefined0 undefined-54.2 undefined
20240 undefined-69.5 undefined-40.48 undefined
20230 undefined-136.39 undefined-95.99 undefined
20220 undefined-127.84 undefined-90.33 undefined
20210 undefined-112.03 undefined-65.38 undefined
20208.75 undefined-107.33 undefined-100.91 undefined
201915.28 undefined-76.93 undefined-60.17 undefined
201810.81 undefined-96.5 undefined-86.85 undefined
201721.15 undefined-43.04 undefined-40.88 undefined
201626.94 undefined-25.81 undefined-22.67 undefined
201582.41 undefined57.42 undefined44.31 undefined
20145.35 undefined-15.29 undefined-15.43 undefined

SanBio Co business model

SanBio Co Ltd is a leading bio-pharmaceutical company focused on the development of products for the treatment of serious neurological diseases. The company was founded in Japan in 2000 and has since become a multinational company with offices in the USA and Europe. Answer: SanBio Co Ltd is a bio-pharmaceutical company that specializes in developing products for the treatment of serious neurological diseases. It was founded in Japan in 2000 and has expanded to become a multinational company with offices in the USA and Europe. SanBio Co is one of the most popular companies on Eulerpool.com.

SanBio Co SWOT Analysis

Strengths

  • Strong research and development capabilities in regenerative medicine.
  • Established partnerships with leading academic institutions and biotech companies.
  • Diverse and innovative product pipeline, addressing critical unmet medical needs.
  • Solid financial position, with sufficient resources for expansion and growth.

Weaknesses

  • Limited market presence and brand recognition compared to larger competitors.
  • Dependence on a few key research programs and products.
  • Vulnerability to regulatory and legal challenges in the healthcare industry.
  • Relatively small workforce, which may limit capacity for simultaneous projects.

Opportunities

  • Growing demand for regenerative medicine solutions as the global population ages.
  • Increasing collaboration opportunities with pharmaceutical companies for product development.
  • Expansion into new geographical markets with high unmet medical needs.
  • Potential to leverage advancements in technology for more efficient and cost-effective therapies.

Threats

  • Intense competition from established pharmaceutical and biotech companies.
  • Stringent regulatory requirements and long approval processes for new therapies.
  • Economic downturns and healthcare system reforms impacting funding and reimbursement.
  • Potential ethical and public perception challenges associated with stem cell therapies.

SanBio Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

SanBio Co historical P/E ratio, EBIT, and P/S ratio.

SanBio Co shares outstanding

The number of shares was SanBio Co in 2023 — This indicates how many shares 57.918 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SanBio Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SanBio Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SanBio Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SanBio Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for SanBio Co.

SanBio Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-18.59 -2.12  (88.61 %)2025 Q1
12/31/2018-16.26 -10.18  (37.4 %)2019 Q3
1

SanBio Co list of shareholders

%
Name
Stocks
Change
Date
8.73852 % Mori (Keita)5,997,28407/31/2023
17.80724 % Kawanishi (Toru)12,221,18607/31/2023
1.73112 % Norges Bank Investment Management (NBIM)1,188,075541,49112/31/2023
1.44612 % Teijin Ltd992,47707/31/2023
0.89828 % Nomura Securities Co., Ltd.616,493345,90012/29/2023
0.79367 % BlackRock Institutional Trust Company, N.A.544,700-12,4003/31/2024
0.76599 % Imamura (Hitoshi)525,70007/31/2023
0.41052 % Charles Schwab Investment Management, Inc.281,74148,3837/31/2023
0.32945 % Simplex Asset Management Co., Ltd.226,10040,6003/31/2024
0.30788 % State Street Global Advisors (US)211,300-2002/29/2024
1
2
3
4
...
5

Most common questions regarding SanBio Co

What values and corporate philosophy does SanBio Co represent?

SanBio Co Ltd represents the values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on advancing regenerative medicine, SanBio is committed to developing novel therapies that address unmet medical needs. By leveraging their proprietary technology, SB623, SanBio aims to restore function and improve the quality of life for patients suffering from neurological disorders. Their dedication to scientific excellence, ethical conduct, and transparency fosters trust among stakeholders. Through their pioneering research and development efforts, SanBio Co Ltd is contributing to advancements in the field of regenerative medicine, bringing hope to patients worldwide.

In which countries and regions is SanBio Co primarily present?

SanBio Co Ltd is primarily present in Japan.

What significant milestones has the company SanBio Co achieved?

Some significant milestones achieved by SanBio Co Ltd include the successful completion of Phase II clinical trials for their investigational therapeutic product SB623, which showed promising results in treating motor deficits caused by stroke. Additionally, SanBio Co Ltd received Fast Track designation from the U.S. FDA for SB623, recognizing its potential to address unmet medical needs. The company also expanded its product pipeline and entered into collaborations with global pharmaceutical companies to further advance their regenerative medicine technologies. SanBio Co Ltd continues to strive towards making notable advancements in the field of regenerative medicine and improving patient outcomes.

What is the history and background of the company SanBio Co?

SanBio Co Ltd is a pioneering regenerative medicine company based in Japan. Founded in 2005, SanBio focuses on developing and commercializing groundbreaking cell-based therapies for neurological disorders. With a strong commitment to advancing scientific research, SanBio has made significant strides in neurorehabilitation and regenerative medicine. The company has successfully conducted clinical trials and received approvals from regulatory authorities, demonstrating the effectiveness and safety of its innovative therapies. SanBio's dedication to improving patients' lives through cutting-edge treatments has earned it a prominent position in the field of regenerative medicine.

Who are the main competitors of SanBio Co in the market?

SanBio Co Ltd faces competition from pharmaceutical companies that operate in the regenerative medicine field. Some of the main competitors include Mesoblast Limited, Athersys Inc., and Healios K.K. These companies are also focused on developing innovative therapies for treating neurological disorders and injuries, similar to SanBio. However, SanBio has established its unique position in the market with its proprietary regenerative cell therapy products.

In which industries is SanBio Co primarily active?

SanBio Co Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of SanBio Co?

The business model of SanBio Co Ltd focuses on developing and commercializing regenerative medicine products. SanBio Co Ltd specializes in the research and development of innovative cell therapies to treat neurological disorders. With a strong emphasis on stem cell-based therapies, the company aims to provide effective and safe treatments for conditions such as traumatic brain injury, stroke, and chronic motor deficits. Through its extensive research, partnership collaborations, and dedication to clinical trials, SanBio Co Ltd aims to revolutionize the field of regenerative medicine and improve the quality of life for patients worldwide.

What is the P/E ratio of SanBio Co 2024?

The SanBio Co P/E ratio is -22.73.

What is the P/S ratio of SanBio Co 2024?

The SanBio Co P/S ratio is 0.

What is the AlleAktien quality score of SanBio Co?

The AlleAktien quality score for SanBio Co is 2/10.

What is the revenue of SanBio Co 2024?

The revenue cannot currently be calculated for SanBio Co.

How high is the profit of SanBio Co 2024?

The SanBio Co profit is -2.64 B JPY.

What is the business model of SanBio Co

SanBio Co Ltd is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological diseases. It was originally founded in Japan and its business model includes research and development, clinical trials, partnerships, and distribution. The research and development team at SanBio focuses on developing novel drugs and therapies based on stem cell and genomic research. They utilize state-of-the-art technologies to identify and optimize novel drug candidates to enable successful treatment of neurological diseases. SanBio is committed to conducting clinical trials by partnering with renowned medical centers and research institutions in Japan, the US, and Europe. This collaboration aims to confirm the effectiveness and safety of clinical candidates for broad use in healthcare. SanBio has also formed partnerships with other companies worldwide for the marketing and distribution of its products. These partnerships aim to make SanBio's products and therapies accessible globally. SanBio offers various therapy products for neurological diseases, including "SB623" for traumatic brain injury and "SB509" for Amyotrophic Lateral Sclerosis (ALS). SB623 is being developed to treat patients with skull-brain injuries. It is a cell therapy derived from reprogrammed human neural stem cells from a donor's bone marrow. SB509 is being developed for the treatment of ALS and is a gene therapy that produces neurotrophic factors to promote the survival of motor neurons. Both products have the potential to meet the need for effective therapies for neurological diseases. In summary, SanBio Co Ltd offers innovative therapeutics for the treatment of neurological diseases. The company's business model includes research and development of novel therapies, conducting clinical trials, partnerships, and product distribution. SanBio has the commitment and resources to meet the demand for effective therapeutics for treating neurological diseases.

What is the SanBio Co dividend?

SanBio Co pays a dividend of 0 JPY distributed over payouts per year.

How often does SanBio Co pay dividends?

The dividend cannot currently be calculated for SanBio Co or the company does not pay out a dividend.

What is the SanBio Co ISIN?

The ISIN of SanBio Co is JP3336750009.

What is the SanBio Co WKN?

The WKN of SanBio Co is A14SRH.

What is the SanBio Co ticker?

The ticker of SanBio Co is 4592.T.

How much dividend does SanBio Co pay?

Over the past 12 months, SanBio Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SanBio Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of SanBio Co?

The current dividend yield of SanBio Co is .

When does SanBio Co pay dividends?

SanBio Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SanBio Co?

SanBio Co paid dividends every year for the past 0 years.

What is the dividend of SanBio Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is SanBio Co located?

SanBio Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von SanBio Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SanBio Co from 9/13/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did SanBio Co pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of SanBio Co in the year 2023?

In the year 2023, SanBio Co distributed 0 JPY as dividends.

In which currency does SanBio Co pay out the dividend?

The dividends of SanBio Co are distributed in JPY.

All fundamentals about SanBio Co

Our stock analysis for SanBio Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SanBio Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.